• For investors wondering whether Bristol-Myers Squibb at around US$56.25 is offering value or risk at this point, this article breaks down what the current price might be indicating about the stock.
• The share price has had a mixed run, with a 7.2% loss over the last week and a 2.5% loss over the last month, but it is still up 5.2% year to date and 26.0% over the past year.
• Recent headlines around Bristol-Myers Squibb have focused on its position within the broader pharmaceuticals space and on how investors are reassessing large drug makers after shifts in sentiment across the sector. This backdrop helps explain why the stock has seen both shorter term pullbacks and stronger performance over longer periods.
• Bristol-Myers Squibb currently has a value score of 5/6. This sets up a closer look at traditional valuation methods next and hints at an even more complete way to think about valuation by the end of this article.

Approach 1: Bristol-Myers Squibb Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth today by projecting the company’s future cash flows and then discounting those back to their present value.

For Bristol-Myers Squibb, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow (FCF) is about $12.0b. Analyst estimates and subsequent extrapolations suggest FCF of around $15.7b in 2026 and $11.8b in 2030, with further projections through 2035 based on Simply Wall St estimates.

Pulling those forecasts together, the DCF model arrives at an estimated intrinsic value of $124.53 per share. Compared with the current share price of about $56.25, this implies a 54.8% discount, indicating that the stock is trading well below this cash flow based estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Bristol-Myers Squibb is undervalued by 54.8%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Bristol-Myers Squibb Price vs Earnings

For a profitable company like Bristol-Myers Squibb, the P/E ratio is a straightforward way to see how much investors are currently paying for each dollar of earnings. The “right” P/E tends to be influenced by expectations for future earnings growth and the perceived risk of those earnings, with higher expected growth and lower risk usually justifying a higher multiple.

Bristol-Myers Squibb trades on a P/E of 15.79x. This is below both the Pharmaceuticals industry average P/E of 16.69x and the broader peer group average of 22.94x. Simply Wall St’s Fair Ratio for Bristol-Myers Squibb is 19.57x, which is its proprietary view of what the P/E “should” be, given factors such as earnings growth characteristics, industry, profit margins, market cap and company specific risks.

The Fair Ratio aims to be more tailored than a simple comparison with industry or peer averages, because it attempts to adjust for the company’s own profile rather than assuming all pharmaceutical stocks deserve the same multiple. Comparing the Fair Ratio of 19.57x to the current P/E of 15.79x suggests the stock is trading below this calibrated benchmark.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Bristol-Myers Squibb Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as simple stories you choose about Bristol-Myers Squibb that connect your view on its future revenues, earnings and margins to a fair value, then compare that fair value to today’s price to help you decide whether the stock looks attractive or stretched.

On Simply Wall St’s Community page, Narratives are presented as an accessible tool where each one links a company story to a full forecast and fair value, then automatically refreshes when new information such as earnings, guidance or drug news is added, so your framework stays current rather than static.

For Bristol-Myers Squibb, one investor might align with a cautious Narrative that ties to a lower fair value near US$45.67 and expects annual revenue contraction of around 8.1% with a future P/E of 14.1x, while another might prefer a more optimistic Narrative closer to US$75.00 that assumes revenue contraction of about 3.4% a year, higher future margins near 23.9% and a future P/E of 18.2x. Comparing each of those fair values to the live share price is what turns the story into a decision tool you can actually use.

For Bristol-Myers Squibb, however, we’ll make it really easy for you with previews of two leading Bristol-Myers Squibb Narratives:

Together these give you a quick sense of how different investors are framing the same facts, one with more focus on upside, the other with more focus on risk.

Fair value in this Narrative: US$65.00 per share

Gap to this fair value from the last close of US$56.25: about 13.5% below the Narrative fair value

Revenue growth assumption: 2.43% a year

• Highlights full year 2024 revenue of US$48.3b and a growth portfolio that generated US$22.6b of those sales.
• Focuses on newer products such as Opdivo Qvantig and Cobenfy alongside cost saving plans that target about US$2b of savings by 2027.
• Blends external fair value work around US$64 to US$66 with P/E based ranges between roughly US$54 and US$67 to anchor the US$65 Narrative estimate.

Fair value in this Narrative: US$45.67 per share

Gap to this fair value from the last close of US$56.25: about 23.2% above the Narrative fair value

Revenue growth assumption: 8.08% annual decline

• Frames loss of exclusivity on key drugs, pricing pressure, higher debt and regulation as longer term headwinds for margins and earnings stability.
• Builds in analyst assumptions of revenue contracting by 8.1% a year with earnings reaching about US$8.1b by 2029 and a future P/E of 14.1x.
• Arrives at a US$45.67 fair value that sits toward the lower end of the analyst target range and is around two standard deviations below a US$62.72 consensus figure.

If you want to go beyond the snapshots and see how the rest of the community is connecting earnings, margins and fair value for this stock, See what the community is saying about Bristol-Myers Squibb

Do you think there's more to the story for Bristol-Myers Squibb? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.